Skip to content
value.today
Vor Biopharma Inc. logo

Vor Biopharma Inc.

Total raised
$110 M
1 round on record
Latest round
$110 M
Jun 2020
First round on record
Jun 2020
Today
Went public
See the company page

Vor Biopharma Inc. is listed today as Vor Biopharma Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vor Biopharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$110 MNo. 1$50 to $250 million

Vor Biopharma Inc.: Raise no. 1, Jun 2020

Investors in this round

33 investors had bought by the notice of Jul 10, 2020: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Vor Biopharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$110 M of $110 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amy Mendel · Executive Officer
  • Nathan Jorgensen · Executive Officer
  • Robert Ang · Executive Officer, Director
  • Joshua Resnick · Director
  • Kush Parmar · Director
  • Sven Lundberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Ang, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 10, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vor Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).

    SEC Form D · Jul 2020

  • The industry group it chose in its notices: Other.

    SEC Form D · Jul 2020

That is all the official record says: Vor Biopharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Vor Biopharma Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Vor Biopharma Inc.
InvestorKindAmountRoundRoleSource
5AM Opportunities I (GP), LLCOthernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
5AM Opportunities I, L.P.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
5AM Partners VI, LLCFund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
5AM Ventures VI, L.P.Venture capitalnot statednot statedHeld Series A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Nathan D. JorgensenPersonnot statednot statedHeld Series B preferred stock (Form 3, 2021)SEC Form 3
PureTech Health LLCOthernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series A-2 and B preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Tirtha ChakrabortyPersonnot statednot statedHeld Series B preferred stock (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 33 investors.

Largest shareholders today

Institutions holding Vor Biopharma Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vor Biopharma Inc.
NameRoleNamed in
Amy MendelExecutive officerJul 2020
Nathan JorgensenExecutive officerJul 2020
Robert AngExecutive officerJul 2020
Joshua ResnickDirectorJul 2020
Kush ParmarDirectorJul 2020
Robert AngDirectorJul 2020
Sven LundbergDirectorJul 2020

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.